Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN versus SPECTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN versus SPECTRACEF.
Cefazolin vs SPECTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily in susceptible gram-positive bacteria.
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV/IM every 6-8 hours; maximum 12 g/day.
400 mg orally twice daily for 10-14 days.
None Documented
None Documented
1.8 hours in normal renal function; extends to 30–70 hours in end-stage renal disease (CrCl <10 mL/min).
Clinical Note
moderateCefazolin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefazolin."
Clinical Note
moderatePhenytoin + Cefazolin
Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment)
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary: <1%; fecal: negligible.
Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The protein binding of Cefazolin can be decreased when combined with Phenytoin."